Prostate cancer: An evolving paradigm

Jorge R. Caso, Vladimir Mouraviev, Matvey Tsivian, Thomas J. Polascik, Judd W. Moul

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.

Original languageEnglish
Pages (from-to)805-809
Number of pages5
JournalJournal of Endourology
Volume24
Issue number5
DOIs
StatePublished - May 1 2010

    Fingerprint

ASJC Scopus subject areas

  • Urology

Cite this

Caso, J. R., Mouraviev, V., Tsivian, M., Polascik, T. J., & Moul, J. W. (2010). Prostate cancer: An evolving paradigm. Journal of Endourology, 24(5), 805-809. https://doi.org/10.1089/end.2009.0539